Company profilePharmaceutical#323 of 1,318 in Pakistan✓ No DRAP alerts

MACQUINS INTERNATIONAL

Pharmaceutical company · 54 brands · 61 molecules

Ranked #75 of 311 companies in Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord)

54 registered products 19 pharmaceutical brands 61 distinct molecules 0 DRAP alerts

Company overview

54
registered products
19
pharmaceutical brands
61
distinct molecules
12
therapeutic classes
0
DRAP alerts

MACQUINS INTERNATIONAL is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 54 product registrations across 61 distinct molecules. Its portfolio is concentrated in Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord) and Other Beta-Lactam, Cephalosporins & Penems. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Top molecules by brand count

Diclofenac3 brands
Sparfloxacin2 brands
Dextran2 brands
Loperamide1 brand
Famotidine1 brand
Ofloxacin1 brand

Therapeutic classes

Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord) · 5Other Beta-Lactam, Cephalosporins & Penems · 4Quinolone Antibacterials · 2Macrolides, Lincosamides And Streptogramins · 2Antidiarrheals, Intestinal Antiinflammatory/Antiinfective · 1Antiinflammatory And Antirheumatic Products · 1Antianemic, Iron Preparations · 1Ectoparasiticides; Scabicides · 1Sulfonamides And Trimethoprim · 1Other Analgesics And Antipyretics · 1Anti-Infective, Ophthalmologicals · 1Antiemetics & Antinauseants · 1

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

Get the full profile for MACQUINS

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.